Pembrolizumab (Keytruda) Cost in India
Most families reach this page holding a prescription with one word on it, and one question behind it: what will this actually cost? A 100 mg Keytruda vial is listed in India at an indicative ₹1.5 lakh to ₹2.1 lakh as of August 2026, and the commonest adult dose needs two vials every three weeks. This page sets out per-vial, per-cycle and full-course figures from published sources, and the assistance routes that exist.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
How much does pembrolizumab (Keytruda) cost per vial and per cycle in India?
Published Indian pharmacy listings put the maximum retail price of a 100 mg Keytruda vial at roughly ₹2.08 lakh as of August 2026, with selling prices commonly reported nearer ₹1.5 lakh to ₹1.9 lakh. The commonest adult schedule, a flat 200 mg every three weeks, needs two vials. That is an indicative ₹3.0 lakh to ₹4.2 lakh of drug per cycle, before day-care and monitoring charges.
100 mg per 4 mL is the only strength marketed in India. Pembrolizumab is approved by the Central Drugs Standard Control Organisation (CDSCO) and marketed here as Keytruda by MSD Pharmaceuticals; the list of indications approved in India is narrower than the US list, and it is the Indian label that governs what your oncologist can prescribe.
| What is being priced | 100 mg vials needed | Indicative cost* | Notes |
|---|---|---|---|
| One 100 mg / 4 mL vial | 1 | ₹1,50,000 – ₹2,10,000 | Listed MRP around ₹2.08 lakh; pharmacy selling price often lower |
| 200 mg flat dose, every 3 weeks | 2 | ₹3,00,000 – ₹4,20,000 per cycle | The commonest adult schedule in India |
| 400 mg flat dose, every 6 weeks | 4 | ₹6,00,000 – ₹8,40,000 per dose | Covers six weeks, so cost per week is similar; fewer hospital visits |
| Weight-based 2 mg/kg dose | 1 – 2, by body weight | ₹1,50,000 – ₹4,20,000 per cycle | Used in some indications and in children; a lighter patient may fit one vial |
| Day care, nursing, pre-dose bloods | — | A few thousand to a few tens of thousands per visit | Billed separately by most hospitals; folded into some quotes and not others |
*Indicative only, as of August 2026. Figures are drawn from published Indian pharmacy price listings and news reporting on Keytruda's Indian pricing — they are not a CION price list, and CION Cancer Clinics quotes no rate against this or any named molecule. Prices change with brand decisions, pharmacy margin, GST treatment and hospital procurement.
One detail decides whether a cycle costs one vial or two: rounding. A 2 mg/kg dose for a 60 kg patient is 120 mg, which still opens a second vial unless the hospital pharmacy can use the remainder for another patient the same day. Whether a quote assumes vial sharing is a fair thing to put to the pharmacy in writing, because it can change the per-cycle figure by more than a lakh.
What does a full course of pembrolizumab cost in India?
A full course is the per-cycle figure multiplied by however many cycles your protocol runs. At the common maximum of 35 three-weekly cycles over about two years, the arithmetic on published prices lands between roughly ₹1.05 crore and ₹1.5 crore for the drug alone. A one-year adjuvant course of 17 to 18 cycles works out to roughly ₹51 lakh to ₹76 lakh. Neither figure includes day care, scans or monitoring.
| Course length | Cycles at 200 mg every 3 weeks | 100 mg vials | Indicative drug cost* |
|---|---|---|---|
| To the first response scan | 3 – 4 | 6 – 8 | ₹9 lakh – ₹17 lakh |
| About 6 months | 8 – 9 | 16 – 18 | ₹24 lakh – ₹38 lakh |
| About 1 year (typical adjuvant course) | 17 – 18 | 34 – 36 | ₹51 lakh – ₹76 lakh |
| About 2 years (common maximum) | 35 | 70 | ₹1.05 crore – ₹1.5 crore |
*These are multiplications of the published per-vial range in the table above, not quotes for any individual patient, and not a CION rate.
Most patients never reach 35 cycles. Treatment stops earlier when scans show the cancer progressing, when a serious immune-related reaction makes continuing unsafe, or by an agreed decision between patient, family and oncologist. Planning against the full two-year ceiling from day one is what pushes many families into selling assets before they need to.
A more workable approach is to budget to the first response assessment, usually after three or four cycles at around nine to twelve weeks, and to re-plan after that scan. That is the point at which your oncologist will know whether the treatment is doing anything for you, and it is the honest decision point for the money as well as the medicine. Where the answer at that scan is no, continuing spend is not the recommended path.
What financial assistance exists for pembrolizumab in India?
No single route funds a full course, and most families end up combining two or three. The main ones are the manufacturer's patient access programme, a government health scheme, a one-time relief-fund grant, and whatever a private insurance policy allows for injectable oncology drugs. Each has its own paperwork, its own ceiling, and its own lead time — starting all of them at once matters more than picking the best one.
- Manufacturer patient access programme MSD has run an access programme for Keytruda in India through hospital pharmacies, historically structured so that after a set number of paid cycles further cycles are supplied at reduced or no drug cost while the patient continues to respond. Terms are revised from time to time, so the current structure should be confirmed in writing by your hospital pharmacy or treating team rather than assumed from an older forum post.
- Government health schemes Ayushman Bharat PM-JAY, Telangana's Aarogyasri, and state employee schemes carry package ceilings that were built around chemotherapy costs. They rarely stretch to a full checkpoint-inhibitor course, and coverage depends on hospital empanelment and the specific package approved for your diagnosis. Scheme ceilings are published as figures; treat any promise of full coverage for a two-year course with scepticism.
- Central and state relief funds The Health Minister's Cancer Patient Fund under the Rashtriya Arogya Nidhi, the Prime Minister's National Relief Fund, and state Chief Minister's Relief Funds all make one-time grants for cancer treatment. They need an application countersigned by the treating hospital, income documentation, and time. They typically fund part of a course, not all of it.
- Private health insurance Cover depends on your policy's injectable-oncology sub-limit, whether day-care oncology is included, and whether the indication is the one approved in India. Off-label use is one of the commonest grounds for rejection. Pre-authorisation for a new immunotherapy protocol also takes longer than for standard chemotherapy, so the paperwork should start well before the first planned cycle.
- Employer, CSR and charitable trusts Some employers, CSR programmes and charitable trusts contribute to high-cost cancer treatment, usually against a hospital estimate rather than a reimbursement claim. Hospital financial counsellors and medical social workers generally know which local trusts are currently active, which is faster than searching for them yourself.
- Clinical trials, as information not as a plan Some trials supply the study drug at no cost to the participant. Eligibility criteria are strict, enrolment is never guaranteed, trials are not available for every cancer type at every stage, and a trial is a research protocol rather than a funding scheme. It is worth knowing the option exists and worth raising with your oncologist; it is not something to count on while budgeting.
- Medical crowdfunding Widely used in India for exactly this cost bracket. The practical trade-offs are platform fees, the need to make a diagnosis public, and the fact that money arrives in instalments rather than as a lump sum, which does not always match a three-weekly treatment schedule.
Who pembrolizumab is not for
Most patients seen in an Indian oncology clinic are not candidates for pembrolizumab. It is approved only for specific cancer types, stages and biomarker results, and if your diagnosis is not on that list, the figures above are not a decision you have to make at all. Eligibility comes first; cost only matters afterwards.
Beyond the indication itself, pembrolizumab is generally unsuitable, or needs specialist reassessment before it is even considered, for people with an active autoimmune disease requiring ongoing systemic immunosuppression; solid-organ transplant recipients, in whom checkpoint blockade can trigger graft rejection; anyone who has already had a severe immune-related reaction to a checkpoint inhibitor; people taking high-dose steroids for another condition; and people who are pregnant or planning a pregnancy. Poor performance status shifts the balance too, because the risk of a serious immune reaction does not fall just because a patient is frailer.
This page is also not a quote for your treatment, not a statement that any particular medicine is available at any particular place, and not a suitability check. Only the oncologist holding your reports can say whether pembrolizumab is an option for your cancer — and that question comes before the price, not after it.
Why do two hospitals quote different prices for the same drug?
Because a quote is rarely just the drug. Each hospital negotiates its own procurement rate with the distributor. Some quotes bundle day-care admission, nursing, pharmacy handling and pre-dose bloods; others show drug only. A quote built on a 200 mg flat dose is nearly double one built on a weight-based dose that fits a single vial. GST treatment and hospital margin move the number again.
A written, itemised estimate is what makes two quotes comparable. The useful line items are: drug cost and the number of vials assumed; the dose and schedule the estimate is based on; day-care and nursing charges per visit; pre-dose blood tests; scan costs and how often scans are planned; and how many cycles the estimate covers. Without those, a single bundled figure from two hospitals is not the same thing twice.
One quote can also already have an access-programme cycle netted off it while the other has not, which makes an apparently cheaper hospital simply an earlier-disclosed one.
Will pembrolizumab get cheaper in India?
Not in the near term. There is no approved and marketed pembrolizumab biosimilar in India as of August 2026, and Indian patent protection on the molecule is expected to begin lapsing only around 2028 to 2029. Indian Express reported in April 2026 that at least seven Indian manufacturers are working on versions, with expectations of a cheaper product in about two years — but nothing is approved yet, and biosimilar timelines slip.
Nivolumab is the useful contrast, because it shows what happens when protection does lapse. Its Indian patent lapsed in May 2026, and a domestic biosimilar launched in January 2026 at roughly a quarter of the reference brand's price. The gap between the two PD-1 medicines is now wide enough that families notice it, and it is a reasonable thing to raise with your oncologist — but only among the drugs actually approved for your cancer and biomarker profile. Nivolumab Cost in India After the Biosimilar Launch sets out those figures, and Nivolumab (Opdivo / Opdyta): What It Is and How It Is Used explains where that molecule is and is not an option.
Pembrolizumab and nivolumab are not interchangeable. They are approved for overlapping but different indications, and swapping one for the other on cost grounds is a clinical decision, not a purchasing one.
Is a vial offered well below the market rate a bargain?
No — it is a warning sign. An International Consortium of Investigative Journalists investigation published in April 2026 documented counterfeit Keytruda reaching patients and even hospitals in several countries, and Indian reporting the same month placed India inside that market. A price far below the published range is the single most common feature of a counterfeit offer, and the patients targeted are precisely the ones who cannot afford the real thing.
Practical protections, none of which cost anything:
- Buy only through a licensed hospital or hospital-empanelled pharmacy with a GST invoice that carries the batch number and expiry printed on the carton. Informal resellers, messaging-group sellers and offers of "leftover stock from another patient" sit outside every safeguard the supply chain has.
- Check the carton before it is opened for a tampered or relabelled seal, a batch number that does not match the invoice, spelling errors, or a vial whose fill level or solution appearance looks unlike previous cycles. Any mismatch is a reason to stop and ask, not to proceed.
- Insist on documented cold chain — pembrolizumab is stored at 2 to 8 degrees Celsius and must never be frozen. A vial delivered warm, frozen, or with no temperature record is unusable regardless of whether it is genuine.
- Report a suspected counterfeit to the hospital pharmacy, the manufacturer's verification line and the state drugs controller. Reporting protects the next patient in the queue even when your own vial turns out to be genuine.
This is patient-safety information, not a sales point. Nothing on this page implies where any medicine should be obtained.
Pembrolizumab Cost in India: Frequently Asked Questions
How much does one vial of Keytruda cost in India?
Published Indian pharmacy listings put the maximum retail price of a single 100 mg per 4 mL Keytruda vial at roughly ₹2.08 lakh as of August 2026, with selling prices commonly reported between about ₹1.5 lakh and ₹1.9 lakh after pharmacy discount. 100 mg is the only strength marketed in India. These figures are indicative, come from published third-party price listings and news reporting rather than from CION, and change with brand pricing decisions and pharmacy margin. The number your hospital bills you can differ, so the only reliable figure is a written quote from your treating hospital's billing desk.
What does one cycle of pembrolizumab cost in India?
It depends on the dose your oncologist prescribes. The commonest adult schedule is a flat 200 mg every three weeks, which needs two 100 mg vials — an indicative ₹3.0 lakh to ₹4.2 lakh of drug per cycle at August 2026 prices. A weight-based 2 mg/kg dose can fit inside a single vial for a lighter patient, halving that figure. A flat 400 mg dose given every six weeks needs four vials at once but covers twice the time, so the cost per week is similar. Day-care admission, nursing, pharmacy handling and pre-dose blood tests are billed on top and are usually a few thousand to a few tens of thousands of rupees per visit.
What does a full course of pembrolizumab cost in India?
A full course is the per-cycle figure multiplied by the number of cycles your protocol runs. On the indicative per-vial range above, a two-year course at the common maximum of 35 three-weekly cycles works out to roughly ₹1.05 crore to ₹1.5 crore of drug alone. A one-year adjuvant course of about 17 to 18 cycles works out to roughly ₹51 lakh to ₹76 lakh. These are arithmetic multiplications of published prices, not quotes, and most patients never reach the maximum cycle count because treatment stops earlier at progression, at a serious immune-related reaction, or by an agreed decision to stop.
What financial assistance exists for pembrolizumab in India?
Several routes exist and most families end up combining them. The manufacturer runs a patient access programme through hospital pharmacies, historically structured so that continuing cycles are supplied at reduced or no drug cost after a set number of paid cycles while the patient is still responding. Government schemes such as Ayushman Bharat PM-JAY and Telangana's Aarogyasri carry package ceilings that rarely stretch to a full checkpoint-inhibitor course. One-time grants are available from the Health Minister's Cancer Patient Fund, the Prime Minister's National Relief Fund and state Chief Minister's Relief Funds. Private insurance may cover part of it, subject to day-care and injectable-oncology sub-limits. No single route funds an entire course.
Does insurance or Aarogyasri cover the cost of pembrolizumab?
Partly at best, and it varies by policy, by scheme and by hospital empanelment. Government scheme packages for cancer day care were designed around chemotherapy costs and their ceilings sit far below a year of checkpoint-inhibitor treatment, so a scheme rarely funds a full pembrolizumab course on its own. Private policies differ on injectable-oncology sub-limits, day-care cover and room-rent linkage, and a common ground for rejection is use outside the indication approved in India. The practical step is to put the exact drug, dose and protocol your oncologist has proposed to your insurer or the hospital's scheme desk and obtain the applicable ceiling in writing before the first cycle.
Is there a cheaper biosimilar version of pembrolizumab in India?
Not as of August 2026. No pembrolizumab biosimilar is approved and marketed in India, and Indian patent protection on the molecule is expected to begin lapsing only around 2028 to 2029. Indian Express reported in April 2026 that at least seven Indian manufacturers are working on versions, with expectations of a cheaper product within about two years, though nothing is approved yet and timelines can slip. Nivolumab is the contrast: its Indian patent lapsed in May 2026 and a domestic biosimilar launched in January 2026 at roughly a quarter of the reference brand's price. Whether that helps you depends entirely on whether nivolumab is approved for your cancer.